Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2022-09-01 00:00:00 ET · period of report 2022-08-31 · accession 0000899243-22-030159 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-01 | 2022-08-31 | DFTX | Karlin Dan | Chief Medical Off | S - Sale | $11.67 | -1,204 | 267.7K | -0.4% | -$14.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-08-31 | S | D | 1,204 | $11.67 | 267,683 | D | — | — | (F2) The Common Shares were sold in one transaction at a price of $15.31 CAD Dollars. This represents the price in United States Dollars using the conversion rate on August 31, 2022. (F3) On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the" Reverse Stock Split"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split. |